Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093190 | 0.91 | HDAC1 (0.46) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL3099655 | 0.90 | HDAC1 (0.47) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL15777571 | 0.89 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL31040490 | 0.88 | ALDH1A1 (0.49) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL903346 | 0.88 | ALDH1A1 (0.49) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL31040491 | 0.88 | ALDH1A1 (0.49) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL15669431 | 0.87 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL17253259 | 0.87 | LMNA (0.47) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL2738375 | 0.84 | LMNA (0.51) | EHMT2EHMT1APOBEC3GALDH1A1LMNA | |
| SCHEMBL20095020 | 0.84 | LMNA (0.45) | EHMT2EHMT1APOBEC3GALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| WO-2017172930-A1 | PBD CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170073452-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2017-03-16 | — | — | US | disclosed |
| US-20170073452-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2017-03-16 | — | — | US | disclosed |
| WO-2015168809-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015106599-A1 | CONJUGATES AND COMPOSITIONS FOR DRUG DELIVERY | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2015-07-23 | — | — | WO | disclosed |
| US-8816122-B2 | Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8653238-B2 | Compositions and methods for transport of molecules with enhanced release properties across biological barriers | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653238-B2 | Compositions and methods for transport of molecules with enhanced release properties across biological barriers | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-7678894-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2008144544-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080286837-A1 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080286837-A1 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1988911-A2 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008069824-A2 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070276018-A1 | AZIRIDINYL-EPOTHILONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276018-A1 | AZIRIDINYL-EPOTHILONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | EHMT2 3336/4885EHMT1 3170/4885APOBEC3G 449/4885 |
| US-20070276018-A1 | AZIRIDINYL-EPOTHILONE COMPOUNDS | CBR3, CBR1, NR0B1 | EHMT2 1489/4885EHMT1 1011/4885APOBEC3G 4793/4885 |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FOLR1, FOLR2, DHFR | EHMT2 2594/4885EHMT1 2252/4885APOBEC3G 4112/4885 |
| US-20080286837-A1 | Nucleotide analogs | NT5C2, NT5E, NUDT1 | EHMT2 1233/4885EHMT1 1283/4885APOBEC3G 196/4885 |
| US-20170073452-A1 | POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF | IDUA, IDE, PUF60 | EHMT2 3695/4885EHMT1 3560/4885APOBEC3G 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.